Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype

Leukemia Research

Volumn 62, Issue , 2017, Pages 84-90

  Hörster, Laura ^a   Schlenk, Richard F ^c   Stadler, Michael ^b   Gabriel, Maria ^b   Thol, Felicitas ^b   Schildmann, Jan ^g,h   Vollmann, Jochen ^d   Rochau, Ursula ^e,f   Sroczynski, Gaby ^e   Wasem, Jürgen ^a   Ganser, Arnold ^b   Port, Matthias ^b,c   Neumann, Anja ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^f Center for Personalized Cancer Medicine GmbH   (Austria)

^g Wilhelm Löhe University of Applied Science   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Cost effectiveness; Markov model; Personalized medicine

Indexed keywords

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; GERMANY; GROSS NATIONAL PRODUCT; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LIFE EXPECTANCY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KARYOTYPING; MOLECULAR BIOLOGY; PROCEDURES;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MOLECULAR BIOLOGY; PRECISION MEDICINE;

EID: 85030660615     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2017.09.009     Document Type: Article

References (35)

1. European Science Foundation Personalised Medicine for the European Citizen, Towards More Precise Medicine for the Diagnosis, Treatment and Prevention of Disease (iPM). 2012.
2. Kalia, M., Personalized oncology: recent advances and future challenges. Metabolism 62:Suppl 1 (2013), S11–S14.
3. Tremblay, J., Hamet, P., Role of genomics on the path to personalized medicine. Metabolism 62:Suppl 1 (2013), S2–S5.
4. Hatz, M.H., Schremser, K., Rogowski, W.H., Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics 32:5 (2014), 443–455.
5. Dohner, H., Weisdorf, D.J., Bloomfield, C.D., Acute myeloid leukemia. N. Engl. J. Med. 373:12 (2015), 1136–1152.
6. Koreth, J., Schlenk, R., Kopecky, K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:22 (2009), 2349–2361.
7. Schlenk, R.F., Dohner, K., Krauter, J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358:18 (2008), 1909–1918.
8. Mrozek, K., Dohner, H., Bloomfield, C.D., Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr. Opin. Hematol. 14:2 (2007), 106–114.
9. De Kouchkovsky, I., Abdul-Hay, M., Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J., 6(7), 2016, 50.
10. Dohner, H., Estey, E.H., Amadori, S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:3 (2010), 453–474.
11. Gaidzik, V., Dohner, K., Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin. Oncol. 35:4 (2008), 346–355.
12. Marcucci, G., Haferlach, T., Dohner, H., Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J. Clin. Oncol. 29:5 (2011), 475–486.
13. Siebert, U., Alagoz, O., Bayoumi, A.M., et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force–3. Value Health 15:6 (2012), 812–820.
14. Briggs, A., Sculpher, M., An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13:4 (1998), 397–409.
15. Sonnenberg, F.A., Beck, J.R., Markov models in medical decision making: a practical guide. Med. Decis. Making 13:4 (1993), 322–338.
16. Weinstein, M.C., O'Brien, B., Hornberger, J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 6:1 (2003), 9–17.
17. Roberts, M., Russell, L.B., Paltiel, A.D., Chambers, M., McEwan, P., Krahn, M., Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med. Decis. Making 32:5 (2012), 678–689.
18. Schlenk, R.F., Dohner, K., Krauter, J., et al. All-Trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia − results of the AMLSG 07-04 randomized treatment trial. ASH Ann. Meet. Abstracts, 118(21), 2011, 80.
19. Briggs, A., Claxton, K., Sculpher, M., Gray, A., Briggs, A., (eds.) Decision Modelling for Health Economic Evaluation, 2011, Oxford University Press, Oxford New York.
20. Miller, D.K., Homan, S.M., Determining transition probabilities: confusion and suggestions. Med. Decis. Making 14:1 (1994), 52–58.
21. Statistisches Bundesamt, Preise. Verbraucherpreisindizes für Deutschland. Jahresbericht. 2012.
22. Kassenärztliche Bundesvereinigung, Einheitlicher Bewertungsmaßstab. Stand: 4. Quartal 2012. 2012.
23. GKV-Spitzenverband, Kassenärztliche Bundevereinigung, Vereinbarung über die qualifizierte ambulante Versorgung krebskranker Patienten „Onkologie-Vereinbarung (Anlage 7 zu den Bundesmantelverträgen). 2009.
24. Tree Age Software Inc. 2015.
25. Eddy, D.M., Hollingworth, W., Caro, J.J., Tsevat, J., McDonald, K.M., Wong, J.B., Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Value Health 15:6 (2012), 843–850.
26. Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6:3 (1997), 217–227.
27. Lang, D.L., Lopert, R., Hill, S.R., Use of pharmacoeconomics in prescribing research. Part 5: modelling–beyond clinical trials. J. Clin. Pharm. Ther. 28:5 (2003), 433–439.
28. World Health Organization, Cost-Effectiveness Thresholds. 2015 ([cited 2015 09.09.2015]; Available from: http://www.who.int/choice/costs/CER_thresholds/en/.).
29. Schlenk, R.F., Kayser, S., Bullinger, L., et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124:23 (2014), 3441–3449.
30. Patel, J.P., Gonen, M., Figueroa, M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366:12 (2012), 1079–1089.
31. Papaemmanuil, E., Gerstung, M., Bullinger, L., et al. Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML. 57th Annual Meeting of the American Society of Hematology; Orlando, 2015.
32. Gerstung, M., Papaemmanuil, E., Martincorena, I., et al. Personally tailored risk prediction of AML based on comprehensive genomic and clinical data. 57th Annual Meeting of the American Society of Hematology. Orlando, 2015.
33. Cressman, S., Karsan, A., Hogge, D.E., McPherson, E., Bolbocean, C., Regier, D.A., Peacock, S.J., Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br. J. Haematol. 174:4 (2016), 526–535.
34. Blommestein, H.M., Verelst, S.G., Huijgens, P.C., Blijlevens, N.M., Cornelissen, J.J., Uyl-de Groot CA: real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann. Hematol. 91:12 (2012), 1945–1952.
35. Leunis, A., Blommestein, H.M., Huijgens, P.C., Blijlevens, N.M., Jongen-Lavrencic, M., Uyl-de Groot, C.A., The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk. Res. 37:3 (2013), 245–250.